NorthView Acquisition Corporation (NVACR)
| Previous close | 0.1480 |
| Open | 0.1400 |
| Bid | 0.1500 x 1000 |
| Ask | 0.1947 x 1800 |
| Day's range | 0.1500 - 0.1799 |
| 52-week range | 0.1500 - 0.1799 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
NorthView Acquisition Corp Announces Filing a Registration Statement on Form S-4 in Connection with a Proposed Business Combination with Profusa, Inc.
Reflects continuing advancement in the business combination process; transaction expected to be completed during the second quarter of 2023New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- NorthView Acquisition Corp (Nasdaq: NVAC) (“NorthView”), a publicly-traded special purpose acquisition company, and Profusa, Inc. (“Profusa”), a digital health company that is pioneering the next generation of personalized medicine, announced that NorthView filed a registration statement on Form S-4 (the “Regist
- GlobeNewswire
Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger with NorthView Acquisition Corp
New York, New York, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa”), a digital health company that is pioneering the next generation of personalized medicine and NorthView Acquisition Corp. “NorthView”) (Nasdaq: NVAC), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) on November 7, 2022 that will result in Profusa becoming a publicly listed company. Upo
